Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $63.4286.

Several equities research analysts have recently commented on DNTH shares. Raymond James Financial restated an “outperform” rating and set a $63.00 price objective (up previously from $56.00) on shares of Dianthus Therapeutics in a report on Tuesday, September 9th. HC Wainwright upped their target price on shares of Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Truist Financial began coverage on Dianthus Therapeutics in a research note on Tuesday, October 14th. They set a “buy” rating and a $56.00 price target for the company. Stifel Nicolaus raised their target price on Dianthus Therapeutics from $52.00 to $65.00 and gave the company a “buy” rating in a report on Friday, September 12th. Finally, Wedbush upped their price target on Dianthus Therapeutics from $44.00 to $46.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 109,031 shares of Dianthus Therapeutics stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the transaction, the executive vice president owned 4,000 shares of the company’s stock, valued at $152,560. This trade represents a 96.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Ryan Savitz sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total value of $903,600.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 216,538 shares of company stock worth $8,283,175 over the last three months. 8.15% of the stock is owned by insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. US Bancorp DE raised its position in Dianthus Therapeutics by 2,013.3% in the first quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after acquiring an additional 1,510 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Dianthus Therapeutics by 0.6% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 168,102 shares of the company’s stock worth $3,049,000 after purchasing an additional 1,081 shares during the period. Invesco Ltd. raised its holdings in shares of Dianthus Therapeutics by 38.7% in the 1st quarter. Invesco Ltd. now owns 15,978 shares of the company’s stock worth $290,000 after purchasing an additional 4,457 shares during the period. Nuveen LLC purchased a new position in Dianthus Therapeutics in the first quarter valued at approximately $1,168,000. Finally, American Century Companies Inc. grew its holdings in Dianthus Therapeutics by 8.7% during the first quarter. American Century Companies Inc. now owns 47,817 shares of the company’s stock valued at $867,000 after purchasing an additional 3,821 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Stock Up 0.8%

NASDAQ:DNTH opened at $41.75 on Friday. Dianthus Therapeutics has a twelve month low of $13.36 and a twelve month high of $45.46. The company has a fifty day moving average of $38.76 and a 200-day moving average of $29.48. The firm has a market capitalization of $1.79 billion, a P/E ratio of -12.00 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The company had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.58 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. On average, analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.